IP Library Granted Patent US 8,173,662
Granted Patent B2
US 8,173,662 · App. 12/455,537 · Granted May 8, 2012

Fused pyrimidines as inhibitors of nucleoside phosphorylases and nucleosidases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,662
App. No.
12/455,537
Granted
May 8, 2012
Kind
B2
Abstract

The present invention relates to compounds of the general formula (I) which are inhibitors of purine muclioside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine mucliosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

Claims (37)

1. A compound of the formula (I):

wherein:

V is selected from CH 2 and NH, and W is NR 1 ; or V is NR 1 , and W is selected from CH 2 and NH;

X is selected from CH 2 and CHOH in the R or S-configuration;

Y is selected from hydrogen, halogen and hydroxy, except where V is selected from NH and NR 1 , then Y is hydrogen;

Z is selected from hydrogen, halogen, hydroxy, SQ, OQ and Q, where Q is an alkyl, aralkyl or aryl group;

R 1 is a radical of the formula (II)

A is N;

B is selected from OH, NH 2 , NHR 6 , SH, hydrogen and halogen, where R 6 is an alkyl, aralkyl or aryl group;

D is selected from OH, NH 2 , NHR 7 , hydrogen, halogen and SCH 3 , where R 7 is an alkyl, aralkyl or aryl group;

E is N;

G is selected from CH 2 and NH, or G is absent, provided that where W is NR 1 and G is NH then V is CH 2 , and provided that where V is NR 1 and G is NH then W is CH 2 ,

or a tautomer thereof, or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1 , where Z is selected from hydrogen, halogen, hydroxy, SQ and OQ.

3. A compound as claimed in claim 1 , where V is CH 2 .

4. A compound as claimed in claim 1 , where X is CH 2 .

5. A compound as claimed in claim 1 , where G is CH 2 .

6. A compound as claimed in claim 1 , where Z is OH.

7. A compound as claimed in claim 1 , where Z is SQ.

8. A compound as claimed in claim 1 , where Z is Q.

9. A compound as claimed in claim 1 , where W is NR 1 .

10. A compound as claimed in claim 1 , where W is selected from NH and NR 1 , and X is CH 2 .

11. A compound as claimed in claim 1 , where V, X and G are all CH 2 , Z is OH and W is NR 1 .

12. A compound as claimed in claim 1 , where V, X and G are all CH 2 , Z is SQ and W is NR 1 .

13. A compound as claimed in claim 1 , where Y is hydrogen.

14. A compound as claimed in claim 1 , where Y is hydroxy.

15. A compound as claimed in claim 1 , where B is hydroxy.

16. A compound as claimed in claim 1 , where B is NH 2 .

17. A compound as claimed in claim 1 , where D is H.

18. A compound as claimed in claim 1 , where D is NH 2 .

19. A compound as claimed in claim 1 , which is:

(3R,4R)-1-[(8-aza-9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4R)-1-[(8-aza-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4R)-3-hydroxy-4-hydroxymethyl-1-(hypoxanthin-9-yl)pyrrolidine; or

(3R,4S)-1-[(8-aza-9-deezaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;

or a pharmaceutically acceptable salt thereof.

20. A pharmaceutical composition comprising a compound as claimed in claim 1 and a carrier.

Assignments (12)
RELEASE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Apr 18, 2023
From: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
To: BIOCRYST PHARMACEUTICALS, INC.
Reel/Frame 063362/0550 →
RELEASE OF SECURITY INTEREST Recorded Apr 6, 2023
From: MIDCAP FINANCIAL TRUST
To: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
Reel/Frame 063348/0762 →
SECURITY INTEREST Recorded Dec 17, 2020
From: BIOCRYST PHARMACEUTICALS, INC.
To: ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP
Reel/Frame 054800/0634 →
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: BIOCRYST PHARMACEUTICALS, INC.; MDCP, LLC
Reel/Frame 054774/0446 →
CONFIRMATORY LICENSE Recorded Apr 23, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048976/0654 →
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →
CHANGE OF NAME Recorded Oct 19, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036888/0817 →
CHANGE OF NAME Recorded Oct 19, 2015
From: COM AFFILIATION, INC.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.
Reel/Frame 036888/0939 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036878/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2015
From: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
To: COM AFFILIATION, INC.
Reel/Frame 036875/0147 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2015
From: CALLAGHAN INNOVATION RESEARCH LIMITED
To: VICTORIA LINK LIMITED
Reel/Frame 035086/0004 →
CHANGE OF NAME Recorded Feb 26, 2015
From: INDUSTRIAL RESEARCH LIMITED
To: CALLAGHAN INNOVATION RESEARCH LIMITED
Reel/Frame 035101/0436 →